New York, May 29, 2026, 19:04 (EDT)
Tevogen Bio Holdings Inc. shares slipped Friday after the company said its planned acquisitions, if they happen, could add around $100 million a year in revenue. The stock, which trades on Nasdaq, finished at $7.91, down 1.6%. Tevogen Bio is off 31.6% for the last five days and has dropped 52.2% so far this year, according to MarketScreener.
Tevogen is trying to shift from a clinical-stage immunotherapy story to a healthcare platform play, pushing the idea of possible near-term revenue. The company hasn’t reported any product revenue so far, and in its latest quarterly filing said it doesn’t expect any unless it gets marketing approval and commercializes TVGN 489 or another candidate.
Tevogen said Thursday its strategic acquisition push now includes a previously announced review of a contract research organization as well as other possible healthcare deals. A CRO supports pharma companies with clinical trials. “Capital discipline and preserving the integrity of our capital structure” remain key, founder and CEO Ryan Saadi said, as Tevogen works to build a “financially self-sufficient healthcare enterprise.” The company noted any transaction still needs due diligence, final documents, and approvals. GlobeNewswire
Tevogen’s latest update comes after its May 21 letter of intent to look at buying a management services organization, or MSO. An MSO can help with admin and operations for healthcare groups. Earlier, the company said it was reviewing a CRO that could bring in over $20 million in yearly revenue and works in 20-plus countries. Tevogen Bio
Tevogen said it lost $5.45 million in the first quarter, not as deep as last year’s $10.37 million loss. At the end of March, it had $692,305 in cash. The company burned through $2.73 million in operating cash over the quarter and said it won’t start a clinical trial unless it gets more funding.
Tevogen made a move with a private investment in May. The company said it struck a $3 million PIPE deal with The Patel Family LLP, which already holds a stake. The investment valued prefunded warrants at $8 each, a 14% premium to the May 11 close, for 375,000 warrants that can convert to common stock.
Competitive signals are still mixed. Tevogen is close to the cell-therapy end of biotech, with Allogene Therapeutics and Iovance Biotherapeutics serving as benchmarks for clinical and commercial execution risk. Allogene shares lost around 2.9% Friday and Iovance was down 4.8%. The SPDR S&P Biotech ETF inched up 0.5%. That points to Tevogen’s move not being just part of a wider biotech decline. Allogene Therapeutics
Downside risks remain. The $100 million isn’t booked revenue, and the acquisitions might not go through. Tevogen faces Nasdaq deadlines too—Oct. 13 for the $50 million market value of listed securities and Oct. 14 for the $15 million market value of publicly held shares. The company said the Nasdaq notices didn’t immediately affect trading. It also said there’s no guarantee it will regain compliance.
That puts the stock less at the mercy of one drug milestone and more on how the company executes. Investors are now looking at signed deals, the cash runway, dilution risk, and Nasdaq compliance. That’s all up against management’s effort to bring in revenue through healthcare services ahead of any product sales from its therapy pipeline.
